SECURITIES AND EXCHANGE COMMISSION
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: April 14, 2003
(Date of earliest event reported)
REGENERON PHARMACEUTICALS, INC.
(State or Other Jurisdiction of
(Commission File Number)
777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
(Address of principal executive offices, including zip code)
Registrants telephone number, including area code: (914) 347-7000
|ITEM 5. OTHER EVENTS|
|ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS|
ITEM 5. OTHER EVENTS
On April 14, 2003, the Company issued a press release announcing the results of its Phase II trial evaluating AXOKINE® for weight loss in overweight and obese people with type 2 diabetes.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
|99a||Press Release dated April 14, 2003|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|REGENERON PHARMACEUTICALS, INC.|
|By:||/s/ Stuart Kolinski|
|Name: Stuart Kolinski
Title: Vice President & General Counsel
|Date: April 16, 2003|